Supplementary Materials

Supplementary Materials for:

JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors

Sizhi P. Gao, Qing Chang, Ninghui Mao, Laura A. Daly, Robert Vogel, Tyler Chan, Shu Hui Liu, Eirini Bournazou, Erez Schori, Haiying Zhang, Monica Red Brewer, William Pao, Luc Morris, Marc Ladanyi, Maria Arcila, Katia Manova-Todorova, Elisa de Stanchina, Larry Norton, Ross L. Levine, Gregoire Altan-Bonnet, David Solit, Michael Zinda, Dennis Huszar, David Lyden,* Jacqueline F. Bromberg*

*Corresponding author. E-mail: dcl2001{at}med.cornell.edu (D.L.); bromberj{at}mskcc.org (J.F.B.)

This PDF file includes:

  • Fig. S1. STAT3 activation and inhibition in TKI-resistant NSCLC.
  • Fig. S2. JAK2 inhibition increases the abundance of pEGFR and pERK in NSCLC.
  • Fig. S3. JAK2 inhibition leads to rapid activation of EGFR/RAS/ERK signaling.
  • Fig. S4. JAK2 links SOCS5 to EGFR, regulating sensitivity to TKI.
  • Fig. S5. Quantification of Western blots in Fig. 4, A and C.
  • Fig. S6. Quantification of Western blots in Fig. 4D.

[Download PDF]

Technical Details

Format: Adobe Acrobat PDF

Size: 1.72 MB


Citation: S. P. Gao, Q. Chang, N. Mao, L. A. Daly, R. Vogel, T. Chan, S. H. Liu, E. Bournazou, E. Schori, H. Zhang, M. Red Brewer, W. Pao, L. Morris, M. Ladanyi, M. Arcila, K. Manova-Todorova, E. de Stanchina, L. Norton, R. L. Levine, G. Altan-Bonnet, D. Solit, M. Zinda, D. Huszar, D. Lyden, J. F. Bromberg, JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors. Sci. Signal. 9, ra33 (2016).

© 2016 American Association for the Advancement of Science